- Report
- January 2024
- 120 Pages
Global
From €5752EUR$5,950USD£4,941GBP
- Report
- February 2024
- 175 Pages
Global
From €4834EUR$5,000USD£4,152GBP
- Report
- January 2024
- 200 Pages
Global
From €4834EUR$5,000USD£4,152GBP
- Report
- April 2024
- 194 Pages
Global
From €4786EUR$4,950USD£4,111GBP
- Report
- February 2024
- 111 Pages
Global
From €4592EUR$4,750USD£3,945GBP
- Drug Pipelines
- April 2024
- 100 Pages
Global
From €1934EUR$2,000USD£1,661GBP
- Drug Pipelines
- January 2024
- 80 Pages
Global
From €1934EUR$2,000USD£1,661GBP
- Report
- December 2023
- 272 Pages
Global
€4829EUR$4,995USD£4,148GBP
- Report
- April 2023
- 175 Pages
Global
From €5703EUR$5,899USD£4,899GBP
- Report
- June 2020
- 114 Pages
Global
From €4592EUR$4,750USD£3,945GBP
- Report
- July 2021
- 50 Pages
China
From €2514EUR$2,600USD£2,159GBP
- Report
- February 2024
- 200 Pages
Global
From €3480EUR$3,600USD£2,990GBP
- Report
- August 2023
- 389 Pages
Global
From €5540EUR$5,730USD£4,758GBP
Oxazolidinones are a class of antibiotics used to treat a variety of bacterial infections. They are bacteriostatic, meaning they inhibit the growth of bacteria, rather than killing them. Oxazolidinones are generally used to treat infections caused by Gram-positive bacteria, such as Staphylococcus aureus and Streptococcus pneumoniae. They are also used to treat infections caused by some Gram-negative bacteria, such as Pseudomonas aeruginosa. Oxazolidinones are generally well-tolerated and have few side effects.
Oxazolidinones are an important part of the antibiotics market, as they are effective against a wide range of bacterial infections. They are often used as a first-line treatment for infections caused by Gram-positive bacteria, and are increasingly being used to treat infections caused by Gram-negative bacteria.
Some companies in the Oxazolidinones market include Merck & Co., Inc., Pfizer, Inc., and Allergan plc. Show Less Read more